Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

“…The aim was to induce stability of disease prior to nephrectomy in over 75% of patients, avoiding potential progression and clinical deterioration during the preoperative surgical period. The PFS and OS results [7.1 months and 22.7 months respectively] were acceptable and in line with those seen for similar risk groups in the pivotal randomized VEGF targeted therapy trials in which the majority of patients previously had nephrectomy [10][11][12] . Survival analysis showed that the prognostic factors in this specific group of patients are similar to those in unselected patients.…”

“…The median duration of therapy prior to surgery was 13 weeks (range [11][12][13][14]. The median size of the primary tumour before and after pazopanib was 10.…”

Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

“…Variable expression of PD-L1, differences in T-cell content or T-cell A CR, as shown in Case 1, is rarely seen in other targeted therapies (less than 1% in first-line sunitinib or pazopanib; ref. 18). It is impossible to predict which patients will achieve such a good response as there are no validated predictive biomarkers despite intense research in this field (17).…”

Current management of renal cell cancer

“…22 Whether there is a gender difference in outcomes in the metastatic population remains to be explored.…”